GlassScriptPhysician profile
Diane M Castro
NPI 1083841522
$3,768.73
in general payments reported to CMS, 2019-2025
25 companies · $1,023 in 2025
The $1,023 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $229 · 2021: $537 · 2022: $707 · 2023: $435 · 2024: $482 · 2025: $1,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,940.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $763.38 | 2021-2025 | Prostep Mica, Augment Injectable, Gravity |
| Musculoskeletal Transplant Foundation INC. | $404.31 | 2022 | |
| Amgen INC. | $401.68 | 2024-2025 | Krystexxa |
| Bioventus LLC | $262.42 | 2019-2025 | Exogen Ultrasound Bone Healing System |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $247.03 | 2019-2025 | Jublia |
| Paratek Pharmaceuticals, INC. | $241.47 | 2023-2025 | Nuzyra |
| Horizon Therapeutics Plc | $176.50 | 2020-2021 | |
| Abbott Laboratories | $171.53 | 2021-2022 | |
| Melinta Therapeutics, LLC | $148.34 | 2019-2023 | Orbactiv, Kimyrsa |
| Pfizer INC. | $119.04 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $97.64 | 2022-2023 | Seglentis |
| Sebela Pharmaceuticals INC. | $95.59 | 2020-2023 | Naftin, Pramosone |
| Nevro Corp. | $90.25 | 2021-2022 | |
| Treace Medical Concepts, INC. | $87.85 | 2022 | |
| Grt US Holding, INC. | $82.32 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $80.69 | 2020-2021 | |
| Zimmer Biomet Holdings, INC. | $68.10 | 2021 | |
| Organogenesis INC. | $48.99 | 2025 | Puraply Wound Matrix |
| Lifenet Health | $42.31 | 2025 | Theragenesis Wound Matrix |
| Gotham Surgical Solutions & Devices, INC. | $29.10 | 2019 | |
| Medtronic, INC. | $28.08 | 2024 | Intellis Adaptivestim |
| Boston Scientific Corporation | $27.17 | 2019 | |
| Globus Medical, INC. | $25.19 | 2025 | Senza |
| Sandoz INC. | $15.35 | 2021 | |
| Dynasplint Systems INC. | $14.40 | 2024 | Dynasplint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Castro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.